Published in Carcinogenesis on September 01, 1998
The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol (2007) 3.68
Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res (2007) 3.43
Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci (2011) 2.48
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci (2013) 1.53
Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol (2003) 1.51
Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci U S A (2009) 1.40
Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev (2013) 1.38
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer (2006) 1.27
Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett (2008) 1.17
Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol (2009) 1.16
Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opin Ther Targets (2011) 1.16
Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat Res (2011) 1.13
Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli. Proc Jpn Acad Ser B Phys Biol Sci (2010) 1.12
Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells. J Nutr (2008) 1.04
The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol (2008) 1.03
Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors. Int J Cancer (2010) 0.97
Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev (2013) 0.95
Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol (2009) 0.94
Ligand promiscuity of aryl hydrocarbon receptor agonists and antagonists revealed by site-directed mutagenesis. Mol Cell Biol (2014) 0.94
Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax. Free Radic Biol Med (2008) 0.93
Ligand-dependent interactions of the Ah receptor with coactivators in a mammalian two-hybrid assay. Toxicol Appl Pharmacol (2007) 0.92
A selective aryl hydrocarbon receptor modulator 3,3'-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res (2012) 0.91
Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One (2014) 0.90
Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med (2006) 0.88
3,3'-diindolylmethane reduces levels of HIF-1alpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem Pharmacol (2008) 0.88
Modulation of CXCR4, CXCL12, and Tumor Cell Invasion Potential In Vitro by Phytochemicals. J Oncol (2009) 0.87
Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Mol Med (2007) 0.87
3,3'-Diindolylmethane stimulates murine immune function in vitro and in vivo. J Nutr Biochem (2007) 0.86
3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett (2010) 0.86
Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4. Mol Cancer (2015) 0.85
The role of estrogen receptor β in transplacental cancer prevention by indole-3-carbinol. Cancer Prev Res (Phila) (2013) 0.84
Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicol Sci (2011) 0.82
Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR. Toxicol Lett (2014) 0.82
Attenuation of Carcinogenesis and the Mechanism Underlying by the Influence of Indole-3-carbinol and Its Metabolite 3,3'-Diindolylmethane: A Therapeutic Marvel. Adv Pharmacol Sci (2014) 0.82
Identification of stanniocalcin 2 as a novel aryl hydrocarbon receptor target gene. J Pharmacol Exp Ther (2012) 0.80
1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer. BMC Cancer (2010) 0.79
3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells. J Nutr Biochem (2013) 0.78
Low levels of 3,3'-diindolylmethane activate estrogen receptor α and induce proliferation of breast cancer cells in the absence of estradiol. BMC Cancer (2014) 0.77
Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell Cycle (2014) 0.77
Defining molecular sensors to assess long-term effects of pesticides on carcinogenesis. Int J Mol Sci (2014) 0.76
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. Semin Cancer Biol (2016) 0.76
Phemindole, a Synthetic Di-indole Derivative Maneuvers the Store Operated Calcium Entry (SOCE) to Induce Potent Anti-Carcinogenic Activity in Human Triple Negative Breast Cancer Cells. Front Pharmacol (2016) 0.75
Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr Rev (2016) 0.75
Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol (1997) 10.61
Visualizing an olfactory sensory map. Cell (1996) 8.79
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ Health Perspect (1998) 6.08
A novel receptor-mediated nuclear protein import pathway. Cell (1996) 6.04
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science (1995) 5.65
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell (1997) 5.28
Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J (1992) 5.23
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
Conduction at domain walls in oxide multiferroics. Nat Mater (2009) 4.18
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm. Mol Cell (2000) 3.86
Two-headed binding of a processive myosin to F-actin. Nature (2000) 3.73
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem (2000) 3.37
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem (1992) 3.13
Issues in the epidemiology and population-based screening of primary angle-closure glaucoma. Surv Ophthalmol (1992) 3.00
Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res (1999) 2.84
Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol (2006) 2.79
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A (1986) 2.62
Population genetic implications from sequence variation in four Y chromosome genes. Proc Natl Acad Sci U S A (2000) 2.62
Leukocytes navigate by compass: roles of PI3Kgamma and its lipid products. Trends Cell Biol (2000) 2.59
Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst (2000) 2.53
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Retention times and electron-capture detector responses of some individual chlorobiphenyls. Bull Environ Contam Toxicol (1972) 2.46
Generation and assembly of secretory antibodies in plants. Science (1995) 2.45
The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N Engl J Med (1990) 2.40
The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol (1998) 2.36
Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation (1999) 2.36
alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors. J Pharmacol Exp Ther (1998) 2.33
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol (1988) 2.27
Factors affecting movement of F-actin filaments propelled by skeletal muscle heavy meromyosin. Am J Physiol (1992) 2.25
Transcriptome analysis and molecular signature of human retinal pigment epithelium. Hum Mol Genet (2010) 2.20
Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. Mol Cell Endocrinol (1998) 2.18
Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure (1998) 2.17
Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J Virol (1991) 2.16
Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev (2000) 2.15
Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem (2000) 2.00
Gating of cystic fibrosis transmembrane conductance regulator chloride channels by adenosine triphosphate hydrolysis. Quantitative analysis of a cyclic gating scheme. J Gen Physiol (1999) 1.92
Differential modulation of proliferation in the neocortical ventricular and subventricular zones. J Neurosci (2000) 1.89
Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol (1997) 1.87
An animal model for acute and persistent Epstein-Barr virus infection. Science (1997) 1.85
Differential display using one-base anchored oligo-dT primers. Nucleic Acids Res (1994) 1.85
Methicillin-resistant Staphylococcus aureus from China characterized by digestion of total DNA with restriction enzymes. Epidemiol Infect (1989) 1.85
An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science (1993) 1.81
Blindness due to cataract: epidemiology and prevention. Annu Rev Public Health (1996) 1.80
Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene (2012) 1.80
The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol (1995) 1.79
Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol (2000) 1.77
An olfactory sensory map develops in the absence of normal projection neurons or GABAergic interneurons. Neuron (1998) 1.76
Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol (1997) 1.72
Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol (1992) 1.71
Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. Toxicol Pathol (1998) 1.70
Malthusian models and Chinese realities: the Chinese demographic system, 1700-2000. Popul Dev Rev (1999) 1.69
Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J Virol (1996) 1.67
The cardiac anesthesia risk evaluation score: a clinically useful predictor of mortality and morbidity after cardiac surgery. Anesthesiology (2001) 1.66
Structure and function of neuronal nicotinic acetylcholine receptors. Prog Brain Res (1996) 1.66
Thyroid disorders in systemic lupus erythematosus. Ann Rheum Dis (1986) 1.66
Immunosuppressive and monooxygenase induction activities of polychlorinated diphenyl ether congeners in C57BL/6N mice: quantitative structure-activity relationships. Toxicol Appl Pharmacol (1990) 1.65
Plasma antioxidants and risk of cortical and nuclear cataract. Epidemiology (1993) 1.63
Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A (2000) 1.62
Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships. Toxicol Appl Pharmacol (1997) 1.61
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene (2011) 1.60
Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. J Virol (1989) 1.60
Rings of anionic amino acids as structural determinants of ion selectivity in the acetylcholine receptor channel. Proc Biol Sci (1991) 1.59
Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol (1999) 1.57
Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem (2001) 1.55
A ring of uncharged polar amino acids as a component of channel constriction in the nicotinic acetylcholine receptor. FEBS Lett (1991) 1.53
Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins and -dibenzofurans with human transthyretin. Chem Biol Interact (1993) 1.52
A case-control study of risk factors for playground injuries among children in Kingston and area. Inj Prev (1998) 1.52
Formation of precise connections in the olfactory bulb occurs in the absence of odorant-evoked neuronal activity. Neuron (2000) 1.52
Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem (1999) 1.50
Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus (1995) 1.50
Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol (1995) 1.49
Polychlorinated biphenyls: metabolic behavior of pure isomers in pigeons, rats, and brook trout. Science (1972) 1.48
Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res (1997) 1.48
Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses. J Virol (2000) 1.46
Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther (2012) 1.45
Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A (2000) 1.45
Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicol Lett (1998) 1.44
The effect of environment on the free and hydrosoluble sterols of Mucor rouxii. Biochim Biophys Acta (1973) 1.44
Chronically administered islet amyloid polypeptide in rats serves as an adiposity inhibitor and regulates energy homeostasis. Pancreatology (2005) 1.43
Assessing sediment contamination in estuaries. Environ Toxicol Chem (2001) 1.43
The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs. J Biol Chem (2000) 1.42
Meta analysis of the association of rs7702187 SNP in SEMA5A gene with risk of Parkinson's disease. Eur Rev Med Pharmacol Sci (2014) 1.40
Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem (1992) 1.40
The acidosis of cholera. Contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap. N Engl J Med (1986) 1.40
Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships. Toxicol Appl Pharmacol (1993) 1.40
Polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs): biochemistry, toxicology, and mechanism of action. Crit Rev Toxicol (1984) 1.39